SR-9009

SR-9009, often referred to as Stenabolic, is a synthetic compound developed by Professor Thomas Burris at Scripps Research Institute. It is not a SARM (Selective Androgen Receptor Modulator), even though it is frequently marketed alongside them. Instead, SR-9009 is a REV-ERBα agonist, which means it binds to and activates the REV-ERBα protein, a key regulator of circadian rhythm and metabolic processes.

​

​

Mechanism of Action:

• REV-ERBα Activation: REV-ERBα is a nuclear receptor involved in the regulation of genes that control circadian rhythm, lipid and glucose metabolism, and energy expenditure.

• Increased Mitochondrial Activity: By activating REV-ERBα, SR-9009 enhances mitochondrial function in skeletal muscle. This increases the efficiency of energy production and utilization.

• Metabolic Effects: It shifts the body toward using more fatty acids as fuel, while reducing fat storage and improving glucose tolerance.

​

Potential Benefits (based on preclinical studies):

1. Fat Loss

2. Promotes higher energy expenditure, even at rest.

3. Encourages the body to burn stored fat for energy.

4. Animal studies show reduced fat mass without changes in diet or exercise.

​

1. Endurance and Stamina:

2. Increases oxidative capacity of muscles, allowing them to perform for longer without fatigue.

3. Sometimes described as creating an “exercise in a pill” effect because of its impact on aerobic performance.

​

Glucose and Lipid Regulation:

1. Improves insulin sensitivity.

2. Lowers triglycerides and LDL cholesterol.

3. May help prevent diet-induced obesity and metabolic syndrome.

4. Circadian Rhythm Support

5. REV-ERBα plays a major role in regulating the body’s biological clock.

6. SR-9009 can influence sleep-wake cycles, although this effect has not been studied extensively in humans.

​

Pharmacokinetics

• Oral Bioavailability: Very poor. SR-9009 degrades quickly when taken orally, which is one of the biggest limitations. This is why researchers often experiment with injectable solutions instead, as the oral route has questionable effectiveness.

​

• Half-Life: Short, around 2–4 hours, requiring multiple doses per day if used consistently.

​

Research Status:

• SR-9009 has only been studied in animals and in vitro.

• No approved human clinical trials exist to confirm its safety, efficacy, or ideal dosing.

• Most data comes from studies on mice, where results showed strong improvements in metabolism, endurance, and fat reduction.

​

Side Effects and Safety Concerns:

• Unknown in Humans: Since it hasn’t undergone clinical testing, the full safety profile is not established.

​

Possible Concerns:

• Liver strain, since it alters metabolic pathways.

• Hormonal effects related to circadian disruption.

• Short half-life requiring frequent dosing, which may stress the system.

​

Practical Use

• In the performance-enhancement community, SR-9009 is sometimes used as a cutting agent for fat loss or as an endurance booster, though this is entirely experimental and not supported by medical approval.

• Injectable formulations are more common among experimenters, given the oral bioavailability issue.

​

Summary:

SR-9009 (Stenabolic) is a synthetic REV-ERBα agonist designed to manipulate the body’s circadian and metabolic functions. It has shown promise in animal studies for fat loss, endurance, and metabolic health, but it lacks human trials and is not approved for medical use. While it is often marketed as a SARM, it operates through a completely different pathway, making it more of a metabolic regulator than a muscle-building agent.

​

Typical Research Community Protocols:

1. Dosage Range

2. Commonly cited doses: 10–30 mg per day.

3. Divided into 2–3 doses per day because SR-9009 has a very short half-life (2–4 hours).

​

Timing:

1. Usually taken in the morning and early afternoon to align with circadian rhythm effects.

2. Some users may add a pre-workout dose if endurance or energy is a goal.

3. Cycle Length

4. Anecdotal cycles range 4–8 weeks.

5. Longer cycles are generally avoided due to lack of safety data.

​

Administration:

1. Oral capsules are common but poorly absorbed.

2. Injectable solutions are preferred in research contexts because they bypass the oral bioavailability problem.

​

Important Notes

• There is no standardized or clinically tested dose for humans.

• Effects on humans are unknown; long-term safety is unstudied.

• SR-9009 should not be considered safe for recreational use.

​

​

Additional Tips (Anecdotal Reports):

• Take doses on an empty stomach if using oral form to improve absorption.

• Monitor for unusual fatigue, insomnia, or digestive issues.

• Short half-life means effects may wear off quickly; spacing doses evenly helps maintain more consistent activity.

• Many users avoid night-time dosing to prevent potential circadian rhythm disruption.